• EN
    • SV
  • About Us
    • Overview
    • Vision, mission, values
    • Our strategy
    • Executive Team
    • Board of Directors
    • Our history
  • Our Science
    • Overview
    • Ion channels
    • Publications/presentations
    • Partnerships & spinouts
    • The discovery process
  • Our Pipeline
    • Overview
    • Tesofensine
    • Tesomet
    • SAN903
    • SAN2219
    • SAN2355
    • SAN2465
    • The development process
  • Patients & Caregivers
    • Overview
    • Hypothalamic obesity
    • Prader-Willi syndrome
    • Epilepsy
    • Rare diseases
  • Investor Relations
    • Overview
    • The Share
    • Financial Calendar
    • Financial reports and filings
    • Analyst Coverage
    • Events and Presentations
    • FAQs
    • Corporate governance
  • Newsroom
    • Overview
    • Press Releases
    • Voices
    • Media Kit
  • Join Us
    • Overview
    • Working with us
    • Current Openings
Saniona
  • EN
  • SV
NEWSROOM

Press Releases

Saniona Icon blue

ABOUT US

Vision, mission, values

Our strategy

Executive team

Board of directors

Our history

OUR SCIENCE

Ion channels

Publications / presentations

Partnerships & spinouts

The discovery process

OUR PIPELINE

Tesofensine

Tesomet

SAN903

SAN2219

SAN2355

SAN2465

The development process

PATIENTS & CAREGIVERS

Hypothalamic obesity

Prader-Willi syndrome

Epilepsy

Rare diseases

INVESTORS

The share

Financial calendar

Financial reports and filings

Analyst coverage

Events and presentations

FAQs

Corporate Governance

NEWSROOM

Press releases

Voices

Media kit

 

JOIN US

Working with us

Current Openings

Saniona
DENMARK

Smedeland 26B
DK-2600 Glostrup
Denmark
+45 7070 5225
saniona@saniona.com

CONNECT 
  • Follow
  • Follow
  • Follow

© 2024 Saniona. All rights reserved.

Privacy Policy